Exicure (XCUR) Long-Term Debt Repayments (2017 - 2022)

Exicure's (XCUR) quarterly Long-Term Debt Repayments came in at $7.5 million in Q1 2022, down 25.0% on a QoQ basis from $10.0 million in Q4 2021.

Exicure (XCUR) Long-Term Debt Repayments (2017 - 2022) Analysis & Trends

Exicure (XCUR) has 4 years of Long-Term Debt Repayments data on file, last reported at $7.5 million in Q1 2022.

Quarterly Long-Term Debt Repayments changed N/A year-over-year to $7.5 million in Q1 2022, while the trailing twelve-month figure through Dec 2022 was $7.5 million (down 25.0% YoY) and the FY2022 annual result came in at $7.5 million, down 25.0% from the prior year.
Long-Term Debt Repayments slipped to $7.5 million in Q1 2022, from $10.0 million in the prior quarter.
In the past five years, Long-Term Debt Repayments ranged from a high of $10.0 million in Q4 2021 to a low of $5.0 million in Q1 2020.
A 3-year average of $7.5 million and a median of $7.5 million in 2022 frame the typical range for Long-Term Debt Repayments.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	17.05 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-10.01 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Exicure	7.27 Mn	7.27 Mn	-	-

Download Data